Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.
By Tom Bronzini / Friday, December 20th, 2013 / Columns, Wine & Viticulture / Comments Off on Showcasing some wines seldom heard of on the grapevine
It’s a lot easier to drink than pronounce the names of the lesser-known Italian varietal wines poured at the Sunland Vintage Winery tasting room in Thousand Oaks.
Atara Biotherapeutics, a Thousand Oaks firm that emerged last year with major Silicon Valley backers and licenses to develop six Amgen assets, has raised $38.5 million to pursue treatments for dialysis complications and ovarian cancer.
By Guest commentary / Friday, November 29th, 2013 / Op/Eds, Opinion / Comments Off on Op/ed: Maintaining the talent flow — How to retain your best workers
The ever-increasing focus on the effective management of people, especially those who are key to an organization’s success, is one of the most important developments in management in the past 15 years. Starting with a seminal McKinsey study in 1998 and the authors’ 2001 book “The War for Talent,” the field of talent management has gained much respect and attention from scholars and practitioners across industries and national boundaries.
Thousand Oaks-based ImmunGene, a cancer treatment firm led by a former Amgen scientist, has raised $9 million from Ally Bridge Group, an investment group with ties to Hong Kong.
ImmunGene’s so-called antibody-cytokine fusion technology could help improve the cancer-cell targeting in therapies. President and CEO Sanjay D. Khare was formerly the scientific director at Amgen, the biotech giant. Prior to the funding, ImmunGene had received several hundred thousand dollars in federal research grants.
Antibody technologies hold promise for creating cancer treatments that do less damage to healthy cells. Molecules are crafted to mimic the body’s own immune system and bind to specific defects in cancer cells.
Thousand Oaks-based ImmunGene, a cancer treatment firm led by a former Amgen scientist, has raised $9 million from Ally Bridge Group, an investment group with ties to Hong Kong.
ImmunGene’s so-called antibody-cytokine fusion technology could help improve the cancer-cell targeting in therapies. President and CEO Sanjay D. Khare was formerly the scientific director at Amgen, the biotech giant. Prior to the funding, ImmunGene had received several hundred thousand dollars in federal research grants.
The 2014 Amgen Tour of California, the largest cycling race in the U.S., will visit four cities in the Tri-Counties in May. The eight-day annual event will roll through Cambria, Pismo Beach and Santa Barbara before concluding at the finish line in Thousand Oaks.
